Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD503 (Intuniv) in children and adolescents with ADHD
NCT00150592Phase 2Completed
- Sponsor
- Takeda
- Start
- May 2005
- Primary completion
- Oct 2005
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of guanfacine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started May 2005; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00150592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00150592.